These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12391600)

  • 1. Beta-secretase as a target for the treatment of Alzheimer's disease.
    Citron M
    J Neurosci Res; 2002 Nov; 70(3):373-9. PubMed ID: 12391600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Alzheimer's disease therapies: inhibition of beta-secretase.
    Citron M
    Neurobiol Aging; 2002; 23(6):1017-22. PubMed ID: 12470797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. beta-Secretase, APP and Abeta in Alzheimer's disease.
    Vassar R
    Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation.
    Luo Y; Bolon B; Kahn S; Bennett BD; Babu-Khan S; Denis P; Fan W; Kha H; Zhang J; Gong Y; Martin L; Louis JC; Yan Q; Richards WG; Citron M; Vassar R
    Nat Neurosci; 2001 Mar; 4(3):231-2. PubMed ID: 11224535
    [No Abstract]   [Full Text] [Related]  

  • 5. Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge.
    Citron M
    Trends Pharmacol Sci; 2004 Feb; 25(2):92-7. PubMed ID: 15102495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent.
    Hartlage-Rübsamen M; Zeitschel U; Apelt J; Gärtner U; Franke H; Stahl T; Günther A; Schliebs R; Penkowa M; Bigl V; Rossner S
    Glia; 2003 Jan; 41(2):169-79. PubMed ID: 12509807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential for BACE1 inhibitors in the treatment of Alzheimer's disease.
    Hussain I
    IDrugs; 2004 Jul; 7(7):653-8. PubMed ID: 15243867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme.
    Rossner S; Lange-Dohna C; Zeitschel U; Perez-Polo JR
    J Neurochem; 2005 Jan; 92(2):226-34. PubMed ID: 15663471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
    Harrison T; Churcher I; Beher D
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
    Pollack SJ; Lewis H
    Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
    Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
    J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.
    Stockley JH; O'Neill C
    Biochem Soc Trans; 2007 Jun; 35(Pt 3):574-6. PubMed ID: 17511655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
    Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
    Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice.
    Asai M; Hattori C; Iwata N; Saido TC; Sasagawa N; Szabó B; Hashimoto Y; Maruyama K; Tanuma S; Kiso Y; Ishiura S
    J Neurochem; 2006 Jan; 96(2):533-40. PubMed ID: 16336629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism.
    Vingtdeux V; Hamdane M; Gompel M; Bégard S; Drobecq H; Ghestem A; Grosjean ME; Kostanjevecki V; Grognet P; Vanmechelen E; Buée L; Delacourte A; Sergeant N
    Neurobiol Dis; 2005 Nov; 20(2):625-37. PubMed ID: 15936948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling.
    Züchner T; Perez-Polo JR; Schliebs R
    J Neurosci Res; 2004 Jul; 77(2):250-7. PubMed ID: 15211591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains.
    Harada H; Tamaoka A; Ishii K; Shoji S; Kametaka S; Kametani F; Saito Y; Murayama S
    Neurosci Res; 2006 Jan; 54(1):24-9. PubMed ID: 16290302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspartic proteases involved in Alzheimer's disease.
    Schmidt B
    Chembiochem; 2003 May; 4(5):366-78. PubMed ID: 12740808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.